SPTX Overview

Seaport Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Its product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder. It is also advancing Glyph2BLS (SPT-348 or Glyph 2-bromo-LSD), a novel, Glyphed oral prodrug of the non-hallucinogenic LSD analog 2-bromo-LSD, in preclinical studies for depressive disorders. GlyphAllo is designed to overcome the bioavailability limitations of allopregnanolone and be durable in MDD.

Wall Street analysts forecast SPTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPTX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Seaport Therapeutics Inc revenue for the last quarter amounts to -27.54M USD, increased 70.18

Seaport Therapeutics Inc. EPS for the last quarter amounts to -20172000.00 USD, decreased -0.43

Seaport Therapeutics Inc (SPTX) has 58 emplpoyees as of June 20 2026.

Today SPTX has the market capitalization of 972.65M USD.